Zevra Therapeutics Inc (ZVRA)
8.64
+0.24
(+2.86%)
USD |
NASDAQ |
Nov 04, 13:06
Zevra Therapeutics Enterprise Value: 451.06M for Nov. 1, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 01, 2024 | 451.06M |
| October 31, 2024 | 437.91M |
| October 30, 2024 | 452.64M |
| October 29, 2024 | 443.69M |
| October 28, 2024 | 432.64M |
| October 25, 2024 | 416.86M |
| October 24, 2024 | 424.75M |
| October 23, 2024 | 430.54M |
| October 22, 2024 | 447.90M |
| October 21, 2024 | 458.43M |
| October 18, 2024 | 455.80M |
| October 17, 2024 | 457.90M |
| October 16, 2024 | 454.22M |
| October 15, 2024 | 450.01M |
| October 14, 2024 | 434.22M |
| October 11, 2024 | 438.43M |
| October 10, 2024 | 425.80M |
| October 09, 2024 | 454.74M |
| October 08, 2024 | 449.48M |
| October 07, 2024 | 418.96M |
| October 04, 2024 | 387.92M |
| October 03, 2024 | 386.87M |
| October 02, 2024 | 383.71M |
| October 01, 2024 | 369.50M |
| September 30, 2024 | 374.24M |
| Date | Value |
|---|---|
| September 27, 2024 | 373.19M |
| September 26, 2024 | 393.71M |
| September 25, 2024 | 406.07M |
| September 24, 2024 | 444.22M |
| September 23, 2024 | 407.91M |
| September 20, 2024 | 433.17M |
| September 19, 2024 | 431.06M |
| September 18, 2024 | 421.07M |
| September 17, 2024 | 405.28M |
| September 16, 2024 | 418.44M |
| September 13, 2024 | 422.12M |
| September 12, 2024 | 408.44M |
| September 11, 2024 | 397.92M |
| September 10, 2024 | 388.97M |
| September 09, 2024 | 389.50M |
| September 06, 2024 | 394.23M |
| September 05, 2024 | 389.50M |
| September 04, 2024 | 387.39M |
| September 03, 2024 | 393.18M |
| August 30, 2024 | 411.60M |
| August 29, 2024 | 397.92M |
| August 28, 2024 | 391.08M |
| August 27, 2024 | 388.44M |
| August 26, 2024 | 381.08M |
| August 23, 2024 | 386.87M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
36.80M
Minimum
May 11 2022
458.43M
Maximum
Oct 21 2024
154.69M
Average
123.40M
Median
Oct 26 2023
Enterprise Value Benchmarks
| Vanda Pharmaceuticals Inc | -116.05M |
| BioCardia Inc | 3.655M |
| Xeris Biopharma Holdings Inc | 634.18M |
| Crinetics Pharmaceuticals Inc | 3.674B |
| Instil Bio Inc | 120.50M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -19.92M |
| Revenue (Quarterly) | 4.449M |
| Total Expenses (Quarterly) | 28.24M |
| EPS Diluted (Quarterly) | -0.48 |
| Gross Profit Margin (Quarterly) | 19.69% |
| Profit Margin (Quarterly) | -447.9% |
| Earnings Yield | -19.44% |
| Normalized Earnings Yield | -21.75 |